Conference Coverage
Conference Coverage
Indirect Comparison Trial Favors Adalimumab for Psoriasis
Major Finding: Through 12 weeks of study participation, adalimumab-treated patients spent an average of 22.4 more days at PASI (Psoriasis Area and...
Conference Coverage
Psoriasis: Short-Course Clobetasol Enhances Etanercept Outcomes
Major Finding: Of psoriasis patients on etanercept plus short-course clobetasol propionate foam, 65% achieved a PASI 75 score at week , compared...
Conference Coverage
Psoriasis Flares Rapidly Postpartum
Conference Coverage
Experience Proved Rituximab Best for Vasculitis
Conference Coverage
Adalimumab May Be Best Anti-TNF for Psoriasis in Obesity
Conference Coverage
Brodalumab Knocks Psoriasis Out of Park
Major Finding: After 48 weeks of treatment with brodalumab, 60% of patients with moderate to severe psoriasis displayed a PASI 100 response.Data...
Conference Coverage
Thalidomide Remains a Good Choice for Refractory Cutaneous Lupus
Conference Coverage
Severe Psoriasis Linked to Doubled Diabetes Risk
Major Finding: New-onset, severe psoriasis doubled the risk for incident diabetes during a median of 6 years compared with people without...
Conference Coverage
Antimalarial Response in CLE Takes Time
Conference Coverage
Psoriasis Severity Linked to Tonsil Size
Major Finding: Patients with psoriasis had an odds ratio of 8.77 for having enlarged tonsils (grade 2 or greater), compared with healthy controls...